Table 1 Active Recruiting Current Clinical Trials with CSF-1R Inhibitors in Various Malignancies
From: Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
NCI Identifier | Study Description | Tumor Type | Drug Combination with CSF-1R inhibitor* | Phase |
|---|---|---|---|---|
NCT02777710 | Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers | Advanced Cancers, Colorectal, Pancreatic Cancer | Durvalumab Pexidartinib(PLX-3397)* | I |
NCT02401815 | PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors | Gastrointestinal Stromal Tumors | PLX-3397* PLX9486 Sunitinib | I/II |
NCT02071940 | PLX3397 KIT in Acral and mucosal Melanoma | Melanoma | PLX-3397* | II |
NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors | Sarcoma, Malignant Peripheral Nerve Sheath Tumors | Sirolimus PLX-3397* | I/II |
NCT03069469 | Study of DCC-3014 in Patients With Advanced Malignancies | Advanced Malignant | DCC-3014* | I |
NCT02880371 | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Advanced Solid Tumors, Platinum Resistant ovarian cancer, pancreatic ductal adenocarcinoma | ARRY-382* Pembrolizumab | I/II |
NCT02829723 | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Advanced Solid Tumors | BLZ945* PDR001 | I/II |